The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Suicidality Emerging From Rapid Venlafaxine Discontinuation: A Challenge–Dechallenge–Rechallenge Case Report
Open accessAbstract
There is ongoing controversy about suicide risk associated with antidepressant use, but much less is known about suicide risk related to discontinuation of antidepressants. Antidepressant withdrawal syndrome (AWS) can be a burdensome syndrome, with well-known symptoms. One possible explanation for this condition is the oppositional model of tolerance. Some study results are suggestive that suicidality can be part of AWS, although the data are still inconclusive. We are aware of only 3 case reports of suicidal behavior with antidepressant discontinuation, which occurred after discontinuation of paroxetine, venlafaxine, and escitalopram. In this case report, we present a patient without a history of suicidal crisis who, in the span of 6 months, experienced 2 suicidal crises, each occurring directly following rapid discontinuation of venlafaxine. Both crises subsided with reintroduction of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Serious symptoms may also include suicidal ideation and behaviour (Bloch et al., 1995; Kostic et al., 2024; Tint et al., 2008).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Kostic et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Valuck, R. J., Orton, H. D., & Libby, A. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04943 · Cited by 106
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
Self-citationAntidepressant withdrawal – the tide is finally turning
Hengartner, M. P., Davies, J., & Read, J. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000465 · Cited by 48
Self-citationSevere psychiatric symptoms associated with paroxetine withdrawal
Bloch, M., Stager, S., Braun, A., & Rubinow, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92691-7 · Cited by 45
Selective serotonin reuptake inhibitor ‘discontinuation syndrome’ or withdrawal
Massabki, I., & Abi-Jaoude, E. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.269 · Cited by 33
Research works printed but not linked: 3
- Hengartner MP, Plöderl M. Newer-generation antidepressants and suicide risk in randomized controlled trials: a re-analysis of the FDA database. Psychother Psychosom. 2019;88(4):247-248.
- P u M e d C r o s s R e f 2. Hayes JF, Lewis G, Lewis G. Newer-generation antidepressants and suicide risk. Psychother Psychosom. 2019;88(6):371-372. · DOI
- P u M e d C r o s s R e f 3. Massabki I, Abi-Jaoude E. Selective serotonin reuptake inhibitor 'discontinuation syndrome' or withdrawal. Br J Psychiatry. 2021;218(3):168-171. · DOI
Cited by
Sorted by citations
Rennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8
Self-citation
Metadata
- Authors
- Kostic, M., Plöder, M., Hengartner, M., & Buzejic, J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2024-01-22
- Volume
- 85
- Issue
- 1
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W4391019364
- Cited by
- 1
- References
- 6
- Citations by year
- 2024: 1
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- dx.doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Zürcher Hochschule für Angewandte Wissenschaften digital collection (Zurich University of Applied Sciences) (submittedVersion, cc-by-nc-nd)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant discontinuation, antidepressant withdrawal syndrome, suicidality, suicide risk, venlafaxine, suicidal crisis
- MeSH terms
- Venlafaxine Hydrochloride, Humans, Suicide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
